405 related articles for article (PubMed ID: 25971426)
1. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.
Dashevsky BZ; Goldman DA; Parsons M; Gönen M; Corben AD; Jochelson MS; Hudis CA; Morrow M; Ulaner GA
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1666-1673. PubMed ID: 25971426
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
3. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
4. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series.
Koolen BB; Vegt E; Rutgers EJ; Vogel WV; Stokkel MP; Hoefnagel CA; Fioole-Bruining A; Vrancken Peeters MJ; Valdés Olmos RA
Ann Nucl Med; 2012 Jan; 26(1):86-91. PubMed ID: 21953212
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients.
Catalano OA; Nicolai E; Rosen BR; Luongo A; Catalano M; Iannace C; Guimaraes A; Vangel MG; Mahmood U; Soricelli A; Salvatore M
Br J Cancer; 2015 Apr; 112(9):1452-60. PubMed ID: 25871331
[TBL] [Abstract][Full Text] [Related]
6. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
7. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
Ulaner GA; Magnan H; Healey JH; Weber WA; Meyers PA
AJR Am J Roentgenol; 2014 Apr; 202(4):859-67. PubMed ID: 24660717
[TBL] [Abstract][Full Text] [Related]
8. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
Du Y; Cullum I; Illidge TM; Ell PJ
J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
[TBL] [Abstract][Full Text] [Related]
9. Disseminated osteomyelitis or bone metastases of breast cancer: (18)F-FDG-PET/CT helps unravel an unusual presentation.
Mandegaran R; Debard A; Alvarez M; Marchou B; Massip P; Wagner T
Ann Nucl Med; 2014 Feb; 28(2):167-71. PubMed ID: 24203488
[TBL] [Abstract][Full Text] [Related]
10. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
11. Focused regional FDG PET/CT detects more osseous metastases than does whole-body PET/CT.
Mojtahedi A; Solomon SB; Ulaner GA
Clin Nucl Med; 2013 Mar; 38(3):217-8. PubMed ID: 23357824
[TBL] [Abstract][Full Text] [Related]
12. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers.
Katayama T; Kubota K; Machida Y; Toriihara A; Shibuya H
Ann Nucl Med; 2012 Jun; 26(5):426-35. PubMed ID: 22477261
[TBL] [Abstract][Full Text] [Related]
14. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
15. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
Sugihara T; Koizumi M; Koyama M; Terauchi T; Gomi N; Ito Y; Hatake K; Sata N
Ann Nucl Med; 2017 Dec; 31(10):719-725. PubMed ID: 28864931
[TBL] [Abstract][Full Text] [Related]
16. [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques].
Withofs N; Collignon J; Rorive A; Jerusalem G; Hustinx R
Rev Med Liege; 2011; 66(5-6):288-90. PubMed ID: 21826964
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.
Fujii T; Yajima R; Kurozumi S; Higuchi T; Obayashi S; Tokiniwa H; Nagaoka R; Takata D; Horiguchi J; Kuwano H
Anticancer Res; 2016 Oct; 36(10):5481-5485. PubMed ID: 27798919
[TBL] [Abstract][Full Text] [Related]
19. 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound.
Avery R; Kuo PH
Clin Nucl Med; 2013 Sep; 38(9):746-8. PubMed ID: 23797230
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy.
Israel O; Goldberg A; Nachtigal A; Militianu D; Bar-Shalom R; Keidar Z; Fogelman I
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1280-4. PubMed ID: 16791597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
